What was the reported incidence of decline in left ventricular ejection fraction when trastuzumab is combined with docetaxel and pertuzumab?

The reported incidence of decline in left ventricular ejection fraction (LVEF) when trastuzumab is combined with docetaxel and pertuzumab is 8.4%. This figure is significant as it reflects the potential cardiac toxicity associated with the use of trastuzumab, particularly when used in conjunction with other chemotherapeutic agents like docetaxel, and targeted therapies such as pertuzumab.

Trastuzumab is an effective treatment for HER2-positive breast cancer but can lead to cardiac complications. Monitoring LVEF is crucial when administering these treatments together, as the risk of heart failure could increase. The 8.4% incidence indicates that while a majority of patients may not experience a decline in LVEF, a notable percentage can still be adversely affected. Understanding this risk is essential for healthcare providers in order to manage patient care effectively and to implement appropriate monitoring and preventive measures during treatment.